NG-350A is an innovative immunotherapy designed to enhance immune response by targeting primary and metastatic tumor sites in rectal cancer. The FORTRESS trial combines NG-350A with standard ...
NG-350A has received FDA fast track designation for mismatch repair-proficient locally advanced rectal cancer, addressing a significant unmet medical need. The drug is an intravenously delivered ...
CAMBRIDGE, Mass., April 17, 2026--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced early data from the ...
Company to disclose clinical safety and efficacy data for NG-350A in combination with chemoradiotherapy following 12-week active treatment period CAMBRIDGE, Mass., March 17, 2026--(BUSINESS ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...
Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy.
Akamis Bio to Present Initial Data from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer at AACR 2026 Company to disclose clinical safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results